Key result
Pharmacogenetic variants explain up to ~55% of metformin response variability in Mexican patients.
Why the study?
Personalized drug and dose selection based on genetic information is imperative in diabetes and hypercholesterolemia, which have high prevalence in Mexico.
Does pharmacogenetic profiling explain the variability in response to antidiabetic and antihypercholesterolemic drugs in Mexican patients?
Does pharmacogenetic profiling explain the variability in response to antidiabetic and antihypercholesterolemic drugs in Mexican patients?
Pharmacogenetic variants significantly influence the response to common antidiabetic and antihypercholesterolemic medications in Mexican patients, highlighting the potential for personalized medicine.
BACKGROUND: Personalized medicine allows the selection of the drug and dose based on the patient's genetic information, which is imperative in the treatment of diabetes and hypercholesterolemia, diseases with high prevalence in Mexico. OBJECTIVE: To integrate pharmacogenetic and genomic research on antidiabetic and antihypercholesterolemic drugs in Mexican patients. MATERIAL AND METHODS: We integrated our research, relating it with similar research from national and foreign laboratories. RESULTS: For antidiabetic pharmacological treatments, variants in the ABCC8 and KCNJ11 genes were consistently associated with the response to sulfonylureas, while variants in the SLC47A1, SLC28A1 and ABCG2 genes explained up to 55% of the variability in the response to metformin. Regarding hypercholesterolemia, atorvastatin treatment is influenced by variants in the genes MTHFR, DRD3, GSTM3, TNFα MDR1, SLCO1BI, ABCB1, CYP2D6, CYP2B6, NAT2 and COMT. CONCLUSION: Our findings highlight the need to integrate pharmacogenetics into clinical practice to achieve greater therapeu tic success in diabetes and hypercholesterolemia.
No takes yet. Share an insight, caveat, or question.
Barrera‐Saldaña et al. (2025) conducted a review in Diabetes and hypercholesterolemia. Pharmacogenetic variants was evaluated on Variability in drug response. Pharmacogenetic variants in specific genes explained up to 55% of the variability in response to metformin and influenced responses to sulfonylureas and atorvastatin in Mexican patients.
Synapse has enriched 5 related papers. Consider them for comparative context: